Evidence map›Paper›PMID 39951229›Full record

ArticleBulletin of experimental biology and medicine2025

A Model of Combination Therapy of Lewis Lung Carcinoma using Resection and Cytostatics.

N N Ermakova, E G Skurikhin, I L Zharkikh, M A Zhukova, V Yu Pan, E S Pan, M Yu Minakova, S G Morozov, A A Kubatiev, A M Dygai

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

N N ErmakovaInstitute of General Pathology and Pathophysiology, Moscow, Russia. nejela@mail.ru.
E G SkurikhinInstitute of General Pathology and Pathophysiology, Moscow, Russia.
I L ZharkikhInstitute of General Pathology and Pathophysiology, Moscow, Russia.
M A ZhukovaInstitute of General Pathology and Pathophysiology, Moscow, Russia.
V Yu PanInstitute of General Pathology and Pathophysiology, Moscow, Russia.
E S PanInstitute of General Pathology and Pathophysiology, Moscow, Russia.
M Yu MinakovaGoldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
S G MorozovInstitute of General Pathology and Pathophysiology, Moscow, Russia.
A A KubatievInstitute of General Pathology and Pathophysiology, Moscow, Russia.
A M DygaiInstitute of General Pathology and Pathophysiology, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We propose a model of combination treatment of Lewis lung carcinoma (LLC) in C57BL/6 mice that includes tumor resection and chemotherapy. A single injection of 5×106 LLC cells into the right lateral subcostal region caused the growth of the primary tumor and its metastasis to the lung. For reducing metastasis and mortality after resection, the primary tumor should be removed with subcutaneous fat on day 8 after inoculation. Antitumor and antimetastatic effects and reduced mortality were achieved by intraperitoneal injection of carboplatin (63.3 mg/kg) and paclitaxel (13.3 mg/kg); chemotherapy was administered twice. The combination of the two approaches increased the survival: the antitumor and antimetastatic effects were observed in 60% of mice with LLC relative to resection alone or treatment with cytostatics alone. However, chemoresistance was formed in 40% of mice, the values of the tumor growth inhibition index and the metastasis inhibition index decreased. This was accompanied by the appearance of cancer stem cells in the circulation with the potential for the formation of spheroids in vitro. The presented model (combination of tumor resection and chemotherapy) can be used in the development of new approaches to improve treatment efficiency in patients with lung cancer.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Lewis LungLung NeoplasmsAnimalsCarboplatinCell Line, TumorCombined Modality TherapyDisease Models, AnimalMaleMiceMice, Inbred C57BLNeoplastic Stem CellsPaclitaxelCarboplatinPaclitaxelcancer stem cellschemotherapyLewis lung carcinomamortalitytumor resection

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.